529 related articles for article (PubMed ID: 15525713)
1. Serum antibody responses after intradermal vaccination against influenza.
Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
[TBL] [Abstract][Full Text] [Related]
2. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
3. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
4. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
6. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y
Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses after dose-sparing intradermal influenza vaccination.
Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
[TBL] [Abstract][Full Text] [Related]
8. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
Chi RC; Rock MT; Neuzil KM
Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
[TBL] [Abstract][Full Text] [Related]
10. Response to a monovalent 2009 influenza A (H1N1) vaccine.
Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
Chiu SS; Peiris JS; Chan KH; Wong WH; Lau YL
Pediatrics; 2007 Jun; 119(6):1076-82. PubMed ID: 17545373
[TBL] [Abstract][Full Text] [Related]
12. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
13. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
[TBL] [Abstract][Full Text] [Related]
14. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
Arnou R; Icardi G; De Decker M; Ambrozaitis A; Kazek MP; Weber F; Van Damme P
Vaccine; 2009 Dec; 27(52):7304-12. PubMed ID: 19849996
[TBL] [Abstract][Full Text] [Related]
15. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
[TBL] [Abstract][Full Text] [Related]
18. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
[TBL] [Abstract][Full Text] [Related]
19. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
